linjc16/ctgov huggingface dataset:
Sarcopenia and Osteopenia in Individuals With Cerebral Palsy and Influences After Botulinum Neurotoxin Type A Injection

Study Overview
=================
Brief Summary
-----------------
Botulinum neurotoxin type A (BoNT-A) intervention to control the hypertonia of muscles is one of the evidence-based managements for children with spastic cerebral palsy. However, BoNT-A injection in animal models to induce weakness had revealed some detrimental effects on muscular and skeletal systems. There are some objectives of this research. The first aim is to establish the baseline data of deficiencies in bone condition and muscle mass for individuals with cerebral palsy. To confirm the influences of intramuscular administration of Botox on muscular and bony health in this population is the other aim.

Detailed Description
-----------------
Individuals with cerebral palsy is vulnerable to osteopenia and sarcopenia. Botulinum neurotoxin type A (BoNT-A) intervention to control the hypertonia of muscles is one of the evidence-based managements for children with spastic cerebral palsy. However, BoNT-A injection in animal models to induce weakness had revealed some detrimental effects on muscular and skeletal systems. There are some objectives of this research. The first aim is to establish the baseline data of deficiencies in bone condition and muscle mass for individuals with cerebral palsy. To confirm the influences of intramuscular administration of Botox on muscular and bony health in this population is the other aim.

Official Title
-----------------
Survey of Sarcopenia and Osteopenia in Individuals With Cerebral Palsy and Examination of Influences After Botulinum Neurotoxin Type A Injection

Conditions
-----------------
Cerebral Palsy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosis of spastic CP (cerebral palsy) moderate to severe spasticity over the limbs, Modified Ashworth Scale score≧2 Exclusion Criteria: fixed contractures of the limbs previous musculoskeletal surgery on the limbs contraindications to botulinum toxin intervention

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Botulinum toxin injection group<br>onabotulinumtoxinA | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| DXA (dual-energy x-ray absorptiometry) | dual-energy x-ray absorptiometry | change from baseline at 24 weeks after botulinum neurotoxin type A injection |
Ultrasound Diagnosis of Antibiotic Associated Diarrhea

Study Overview
=================
Brief Summary
-----------------
The hypothesis is that there are unique sonographic characteristics of antibiotic-associated diarrhea. We will compare the ultrasound findings in patients who received antibiotics and developed diarrhea to toxin analysis for clostridium difficile in stool in order to find differences in the sonographic findings in the positive and negative cases.

Conditions
-----------------
Antibiotic-Associated Diarrhea

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: admitted patients who developed diarrhea in 72 hours since the beginning of admission patients age above 18 years. patients received antibiotics during admission Exclusion Criteria: other reasons of diarrhea drugs induced diarrhea length of time since the beginning of diarrhea is shorter than 72 hours. patients had diarrhea during the first day of admission

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
focus, study, evaluate, sonographic, findings, colon, patients, developed
Incidence, Long- Term Outcome and Factor Related to Non- Cardiac Postoperative Delirium in Elderly Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the incidence, long term outcome and factor related to postoperative delirium in elderly patients after non-cardiac surgery.

Detailed Description
-----------------
The investigators have process of quality assurance for the study including data dictionary, data verification of case record form and site monitoring and auditing.

Official Title
-----------------
Incidence, Long- Term Outcome and Factor Related to Non- Cardiac Postoperative Delirium in Elderly Patients (POD-I)

Conditions
-----------------
Postoperative Delirium

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >/ 60 years American Society of Anesthesiologists (ASA) physical status 1-3 Undergoing scheduled surgery Giving an informed consent Exclusion Criteria: Impaired visual and auditory disturbance Cannot communicate with Thai language Undergoing neurosurgery

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Delirium<br>Patients with delirium and patients without delirium | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of postoperative delirium | participants will be followed for the duration of hospital stay, an expected average of 1 week. | participants will be followed for the duration of hospital stay, an expected average of 1 week. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Factor related to postoperative delirium | Anesthetic technique, Pain score, type of operation | participants will be followed for the duration of hospital stay, an expected average of 2 weeks | 
| Long-term outcomes (cognitive impairment) | This outcome will measure only patients who develop delirium after operation. | 3 and 6 months after operation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Delirium, postoperative delirium, elderly
Observational Study of NovoMix® 50 for Treatment of Type 2 Diabetics for 12 Months

Study Overview
=================
Brief Summary
-----------------
This study is conducted in Europe. The aim of this observational study is to evaluate the blood glucose control when using NovoMix® 50 up to 12 months after initiation subjects with type 2 diabetes currently on a therapy with human biphasic insulin. An additional objective is also to observe the different regimes of starting and maintaining the treatment with NovoMix® 50 during one year.

Official Title
-----------------
A Prospective, Multicentre, Open Label, Un-controlled , Observational, 12-month Study in Subjects Using: NovoMix® 50 (Biphasic Insulin Aspart 50) for Treatment of Type 2 Diabetes Mellitus in Slovenia

Conditions
-----------------
Diabetes, Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Drug: biphasic insulin aspart 50


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 diabetes treated with biphasic human insulin with or without metformin Inadequate glycaemic control or is experiencing hypoglycaemic events or would, in the physician's opinion, benefit from treatment with NovoMix® 50 Exclusion Criteria: Subjects with diagnosed type 1 diabetes mellitus Subjects treated with short acting or intermediate acting human insulin or any insulin analogue Subjects who are unlikely to comply with study description, e.g. uncooperative attitude, inability to come for regular visits Subjects with a hypersensitivity to biphasic insulin aspart 50 (NovoMix® 50 )or to any of the excipients Women of childbearing potential, who are pregnant, breast-feeding or intend to become pregnant within next 12 months
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| A<br> | Drug: biphasic insulin aspart 50<br>* Efficacy and safety data collection in connection with the use of the drug NovoMix® 50 in daily clinical practice.<br>* Other names: NovoMix® 50;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in HbA1c |  | At 0, 3, 6, 9, 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of subjects achieving target HbA1c |  | At 0, 3, 6, 9, 12 months | 
| Change in FPG (fasting plasma glucose) |  | At 0, 3, 6, 9, 12 months | 
| Change in PPG (postprandial glucose) |  | At 0, 3, 6, 9, 12 months | 
| Change in number of hypoglycaemic events |  | At 0, 3, 6, 9, 12 months | 
| Change in insulin presentation |  | At 0, 3, 6, 9, 12 months | 
| Dose and number of injections |  | At 0, 3, 6, 9, 12 months | 
| Number of ADRs (adverse drug reaction) |  | At 0, 3, 6, 9, 12 months |
A Comparison of Morphine and Morphine Plus Dexmedetomidine in Chronic Cancer Pain

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether dexmedetomidine added to morphine is effective in the treatment of chronic cancer pain.

Detailed Description
-----------------
We conduct the study in Cukurova University Faculty of Medicine Research Hospital after obtaining ethics committee approval and patient's informed consent. Patients with cancer pain are allocated into two group to receive Patient Controlled Analgesia with morphine or morphine plus dexmedetomidine.

Official Title
-----------------
A Comparison of Morphine and Morphine Plus Dexmedetomidine in Chronic Cancer Pain

Conditions
-----------------
Chronic Pain

Intervention / Treatment
-----------------
* Drug: Morphine
* Drug: Morphine plus dexmedetomidine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with chronic cancer pain between 20-80 years old age Exclusion Criteria: the presence of severe systemic disease(cardiac, pulmonary, hepatic or renal) psychiatric or neurologic disease unable to communicate verbally nausea and vomiting patient's refusal

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Control<br>Morphine, 0.02 mg/kg PCA bolus dose with 10 minutes lock-out interval | Drug: Morphine<br>* Morphine, 0.02 mg/kg PCA bolus dose with 10 minutes lock-out interval<br>* Other names: morphine sulphate;|
| Active Comparator: Morphine plus dexmedetomidine<br>Morphine 0.02 mg/kg plus dexmedetomidine 0.1 microgram/kg PCA bolus dose with 10 minutes lock-out interval | Drug: Morphine plus dexmedetomidine<br>* Morphine 0.02 mg/kg plus dexmedetomidine 0.1 microgram/kg PCA bolus dose with 10 minutes lock-out interval<br>* Other names: Morphine sulphate plus dexmedetomidine;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Morphine consumption (mg) | cumulative morphine consumption for 24 hours | 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain score | visual analog scale to assess pain degree | 24 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Morphine, Chronic pain, Dexmedetomidine
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients

Study Overview
=================
Brief Summary
-----------------
A clinical observational study for patients with HIV co-infected with hepatitis C that investigates the levels of their health literacy, hepatitis C and HIV knowledge. Participants will complete a one-time assessment of these studied domains and categorized in three groups defined by their hepatitis C treatment referral status: not-referred, referred-attended, referred and no-show.

Detailed Description
-----------------
The main purpose of this research study is to investigate the prevalence of inadequate health literacy and hepatitis C knowledge and their determinants among people living with HIV/AIDS co-infected with hepatitis C. The observation will determine if health literacy and/or hepatitis C knowledge are predictors of patient willingness and intention to be treated for HCV in the overall cohort and stratified according to study groups as noted above.

Official Title
-----------------
Effects of Health Literacy and Hepatitis C Knowledge on Hepatitis C Treatment Willingness in HIV-coinfected Patients, According to Hepatitis C Treatment Referral Status

Conditions
-----------------
Hepatitis C, Hepatitis C, Chronic, HIV/AIDS

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any adult (≥ 18 years) HIV-infected patient attending the UCSD Owen Clinic Regardless of ethnic background English or Spanish speaking With active HCV infection defined as having a detectable HCV viral load with or without a positive HCV antibody Exclusion Criteria: Neurocognitive impairment precluding participation Physical illness precluding participation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Not referred for HCV therapy<br> | |
| Referred for HCV therapy,did not show up<br> | |
| Referred,attended HCV therapy evaluation<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Inadequate health literacy (s-TOFHLA inventory) | The primary outcome will measure the point prevalence of inadequate health literacy among persons with HIV/AIDS with active hepatitis C infection. | Baseline before HCV treatment consideration | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hepatitis C knowledge (using the modified Treolar's scale) |  | Baseline before HCV treatment consideration | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV, Health literacy, Hepatitis C, Hepatitis C knowledge, HIV knowledge, Hepatitis C treatment
MEP and Neuromuscular Blocker

Study Overview
=================
Brief Summary
-----------------
It is important to predict the influence of the neuromuscular blocking agents on the motor evoked potential. Investigator will investigate the dose-response relationship between the degree of the neuromuscular blockade and the motor evoked potential in patients undergoing brain tumor surgery using the population approach. Investigator will investigate the influence of the other factors such as the impedence, reactance, muscel amount, and age on the motor evoked potential.

Official Title
-----------------
Quantitative Analysis Between Neuromuscular Blocking Agent and Motor Evoked Potential and Analysis of Risk Factors for the Coefficient of Variance of Motor Evoked Potential in Patients Undergoing Brain Tumor Removal Surgery: Population Approach

Conditions
-----------------
Brain Tumor

Intervention / Treatment
-----------------
* Drug: Arm I (MEP)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. Patients aged 19 years old or older, with American Society of Anesthesiologists Physical Status 1-3, and scheduled for elective brain tumor surgery under the monitoring of the motor evoked potential Exclusion Criteria: Central or peripheral neuromuscular disease Sensory or motor nerve disorder Allergy to propofol, remifentanil, and rocuronium Patients with pacemaker

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: rocuronium<br>Neuromuscular blockade will be performed using rocuronium. | Drug: Arm I (MEP)<br>* Arm I (MEP): Motor evoked potential will be measured in various degree of the neuromuscular blockade.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Amplitude of the motor evoked potential | Amplitude of the motor evoked potential will be evaluated at intraoperative 0 h from the start of the anesthetic induction. | At intraoperative 0 hr from the start of the anesthetic induction | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Amplitude of the motor evoked potential | Amplitude of the motor evoked potential will be evaluated at intraoperative 0 h from the opening of the dura. | At intraoperative 0 h from the opening of the dura |
Assessment of Mediastinal Masses With Diffusion Weighted MR Imaging

Study Overview
=================
Brief Summary
-----------------
Differentiation between benign and malignant mediastinal tumors as well as characterization and grading of malignancy which is essential for treatment planning as well as for prognosis

Detailed Description
-----------------
Differentiation between benign and malignant mediastinal tumors as well as characterization and grading of malignancy is essential for treatment planning as well as for prognosis . MRI presents valuable diagnostic information in assessing the mediastinum. In addition, special applications have been developed over recent years diffusion-weighted magnetic resonance imaging is one such technique The advent of echo-planar imaging technique has rendered diffusion weighted imaging of the abdomen and thoracic cavity possible . Quantitative assessment of the mediastinal mass is possible by calculation of apparent diffusion co-efficient value ,which is related to the proportion of extracellular and intracellular component. The apparent diffusion co-efficient is inversely correlated with tissue cellularity. It is lower in viable tumor tissue with densely packed diffusion-hindering obstacles than in tissue with less densely packed obstacles such as tumor necrosis and benign tissue .

Official Title
-----------------
Assessment of Mediastinal Masses With Diffusion Weighted MR Imaging

Conditions
-----------------
Mediastinal Tumor

Intervention / Treatment
-----------------
* Radiation: MRI diffusion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any age groups diagnosis of mediastinal mass (by Multislice Computed Tomography). Exclusion Criteria: chemotherapy radiotherapy. thoracic surgery. cystic mass . mass with large amount of necrosis or calcification. contraindication of MRI (e.g. pacemakers , claustrophobia).
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Radiation: MRI diffusion|using MRI diffusion to differentiate between benign and malignant mediastinal masses|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| sensitivity and specificity of magnetic resonance imaging diffusion in mediastinal masses |  | up to one month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
mediastinal masses, MRI diffusion
Transnasal Humidified Rapid Insufflation System for Intubation

Study Overview
=================
Brief Summary
-----------------
Transnasal humidified rapid insufflation ventilator exchange (THRIVE) or not during the anesthesia induction

Detailed Description
-----------------
Control group-usual mask ventilation during apnea for anesthetic intubation and check tube positioning THRIVE group-applying THRIVE during apnea for anesthetic intubation and check tube positioning

Official Title
-----------------
Effect of Transnasal Humidified Rapid Insufflation Ventilator Exchange During Anesthesia Induction With Double Lumen Endotracheal Tube

Conditions
-----------------
Hypoxemia

Intervention / Treatment
-----------------
* Device: Transnasal humidified rapid insufflation ventilator exchange
* Device: Conventional face mask


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who scheduled for elective lung surery with one lung ventilation Exclusion Criteria: suspicious difficult intubation (BMI >35kg/m2, mouth opening < 3 finger, Mallampati G >3), Room air SpO2 < 90%, active pulmonary infection, emergency operation, pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Applying Transnasal humidified rapid insufflation ventilator exchange
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Control<br>usual mask ventilation during anethesia induction | Device: Conventional face mask<br>* applying oxygen using usual face mask<br>|
| Active Comparator: THRIVE<br>Applying Transnasal humidified rapid insufflation ventilator exchange during anesthesia induction | Device: Transnasal humidified rapid insufflation ventilator exchange<br>* applying 40L of oxygen for 1min and afte that increase oxygen flow up to 70L for 1 min.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Desaturation | number of patients who experienced SpO2 under 93% | during the anesthesia induciton |